Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Multi-center, Phase II Clinical Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

NCT04839510 is registered in ClinicalTrials.gov with Shanghai Miracogen Inc. as lead sponsor.

NCT NCT04839510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04839510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Multi-center, Phase II Clinical Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer
Lead sponsor
Shanghai Miracogen Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
April 20, 2021
Completion date
September 30, 2022
Enrollment
58 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced urothelial cancer, metastatic urothelial carcinoma